Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

NCT01297400 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Burns

Interventions

DRUG: Investigational Drug, MW-III
DRUG: Silvadene® Cream 1% [Silver Sulfadiazine]

Sponsor

Skingenix, Inc.